Perspective Therapeutics appoints Maya Martinez-Davis as independent director.

Perspective Therapeutics has appointed Maya Martinez-Davis as an independent director to its Board of Directors. Martinez-Davis is President of GSK's U.S. Commercial business and has previously held positions at Merck KGaA and Pfizer. She brings extensive experience in the biopharmaceutical industry, with expertise in oncology, specialty, respiratory, and vaccines. Martinez-Davis's appointment is effective immediately.

September 02, 2025

Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, has appointed Maya Martinez-Davis as an independent director to its Board of Directors, effective immediately. Martinez-Davis is currently the President of GSK's U.S. Commercial business and brings extensive experience in the biopharmaceutical industry, having previously held executive positions at Merck KGaA and Pfizer.

Prior to joining GSK, Martinez-Davis served as President of biopharma Latin America at Merck KGaA and Senior Vice President and Head of Global Oncology for its biopharma business. She has over a decade of experience in senior executive roles at Pfizer, focusing on oncology, vaccines, and specialty portfolios. Additionally, she has served on the Board of Directors of Mirati Therapeutics, Inc., a clinical-stage biotechnology company focused on targeted oncology therapies, from 2018 until its acquisition by Bristol Myers Squibb in January 2024.

Martinez-Davis holds an undergraduate degree from Saint Louis University and a Master’s in business leadership and marketing from the IE Business Institute in Madrid, Spain. Her appointment to Perspective Therapeutics' Board of Directors underscores the company's commitment to leveraging her commercial and clinical development expertise to advance its clinical programs and deliver innovative treatments for cancer patients.

Lori Woods, Chairperson of Perspective, commented, "The Board and I are excited to welcome Maya and look forward to working with her as we continue to guide the Company towards building long-term shareholder value. Maya brings a phenomenal breadth of experiences, which we believe are highly complementary to the experience of our existing directors and Perspective’s management team. We believe she will be a strong steward for shareholders in helping advance our clinical programs and deliver on our goal of helping cancer patients with limited treatment options."

Thijs Spoor, Perspective’s CEO, said, "I welcome the opportunity to work with Maya. Her commercial and clinical development experience in oncology will be a valuable resource for the Perspective team. We are at an exciting time in the Company’s history, as we are excited by the potential of our cutting-edge science to produce innovative new medicines that could improve patients’ lives."

Martinez-Davis stated, "I am excited to join Perspective’s Board at such a pivotal time in the rapidly evolving radiopharma field, and to help demonstrate the promise of alpha emitting radioisotopes in the treatment of cancers throughout the body. I look forward to sharing my insights and experience with the Perspective team, as the Company advances its three clinical-stage programs with potential to transform cancer treatment."

Perspective Therapeutics is developing proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. [1].

References:
[1] https://www.stocktitan.net/news/CATX/perspective-therapeutics-appoints-maya-martinez-davis-to-board-of-lyk17u63u8qn.html
[2] https://www.ainvest.com/news/gsk-strategic-expansion-kidney-disease-therapeutics-orphan-drug-designation-catalyst-long-term-creation-2508/